PL2814587T3 - Chromatografia powinowactwa oparta na receptorze Fc - Google Patents
Chromatografia powinowactwa oparta na receptorze FcInfo
- Publication number
- PL2814587T3 PL2814587T3 PL13704599T PL13704599T PL2814587T3 PL 2814587 T3 PL2814587 T3 PL 2814587T3 PL 13704599 T PL13704599 T PL 13704599T PL 13704599 T PL13704599 T PL 13704599T PL 2814587 T3 PL2814587 T3 PL 2814587T3
- Authority
- PL
- Poland
- Prior art keywords
- affinity chromatography
- based affinity
- receptor based
- receptor
- chromatography
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
- B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
- B01J20/289—Phases chemically bonded to a substrate, e.g. to silica or to polymers bonded via a spacer
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/166—Fluid composition conditioning, e.g. gradient
- B01D15/168—Fluid composition conditioning, e.g. gradient pH gradient or chromatofocusing, i.e. separation according to the isoelectric point pI
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
- B01J39/26—Cation exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12155630 | 2012-02-15 | ||
| EP13704599.3A EP2814587B1 (en) | 2012-02-15 | 2013-02-14 | Fc-receptor based affinity chromatography |
| PCT/EP2013/052932 WO2013120929A1 (en) | 2012-02-15 | 2013-02-14 | Fc-receptor based affinity chromatography |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2814587T3 true PL2814587T3 (pl) | 2018-10-31 |
Family
ID=47720509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13704599T PL2814587T3 (pl) | 2012-02-15 | 2013-02-14 | Chromatografia powinowactwa oparta na receptorze Fc |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150018241A1 (pl) |
| EP (1) | EP2814587B1 (pl) |
| JP (3) | JP6152120B2 (pl) |
| KR (1) | KR102069397B1 (pl) |
| CN (1) | CN104125852B9 (pl) |
| BR (1) | BR112014018005B1 (pl) |
| CA (2) | CA2860600C (pl) |
| ES (1) | ES2676031T3 (pl) |
| HR (1) | HRP20180966T1 (pl) |
| MX (1) | MX360352B (pl) |
| PL (1) | PL2814587T3 (pl) |
| RU (1) | RU2624128C2 (pl) |
| SI (1) | SI2814587T1 (pl) |
| TR (1) | TR201808458T4 (pl) |
| WO (1) | WO2013120929A1 (pl) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6292718B2 (ja) | 2011-07-01 | 2018-03-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 凝集ポリペプチドから単量体ポリペプチドを分離するための方法 |
| SG10201800492PA (en) | 2013-04-29 | 2018-03-28 | Hoffmann La Roche | Human fcrn-binding modified antibodies and methods of use |
| EP2992010B1 (en) | 2013-04-29 | 2021-03-24 | F.Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| EP3835318B1 (en) * | 2014-01-15 | 2025-10-29 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
| BR112016014969A2 (pt) | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
| EP3119490B1 (en) * | 2014-03-21 | 2021-09-08 | F. Hoffmann-La Roche AG | In vitro prediction of in vivo half-life of antibodies |
| EP3162895B1 (en) * | 2014-06-27 | 2020-11-25 | Tosoh Corporation | Improved fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent |
| AR101753A1 (es) | 2014-09-03 | 2017-01-11 | Boehringer Ingelheim Int | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO |
| EP3215528B1 (en) | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| UA125433C2 (uk) | 2015-07-23 | 2022-03-09 | Бьорінґер Інґельхайм Інтернаціональ Ґмбх | Націлена на іl-23а і фактор активації в-лімфоцитів (baff) сполука та її застосування |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| US20180319838A1 (en) | 2015-11-04 | 2018-11-08 | Biogen Ma Inc. | Conjugation methods for modifying or immobilizing proteins |
| JP2018039735A (ja) * | 2016-09-05 | 2018-03-15 | 東ソー株式会社 | 補体依存性細胞傷害活性が異なる抗体の分離方法 |
| CN109689682B (zh) | 2016-09-19 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 基于补体因子的亲和层析 |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| MX2019006954A (es) | 2016-12-20 | 2019-08-01 | Hoffmann La Roche | Terapia de combinacion de anticuerpos biespecificos anti-cd20/anti-cd3 y agonistas de 4-1bb (cd137). |
| JP7148539B2 (ja) | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| SG11201909218RA (en) | 2017-04-03 | 2019-11-28 | Hoffmann La Roche | Antibodies binding to steap-1 |
| EP4201953A1 (en) | 2017-04-03 | 2023-06-28 | F. Hoffmann-La Roche AG | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| KR102294136B1 (ko) | 2017-04-05 | 2021-08-26 | 에프. 호프만-라 로슈 아게 | 항-lag3 항체 |
| CA3058279A1 (en) | 2017-04-13 | 2018-10-18 | F.Hoffmann-La Roche Ag | An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer |
| CN110573626B (zh) * | 2017-04-28 | 2024-05-03 | 豪夫迈·罗氏有限公司 | 抗体选择方法 |
| GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
| JP6977536B2 (ja) * | 2017-12-19 | 2021-12-08 | 東ソー株式会社 | ゲル濾過クロマトグラフィを用いた抗体の変性度合評価方法 |
| BR112020011469A2 (pt) | 2017-12-21 | 2020-11-24 | F. Hoffmann-La Roche Ag | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, uso do anticorpo, método de tratamento de uma doença e invenção |
| WO2019129679A1 (en) | 2017-12-29 | 2019-07-04 | F. Hoffmann-La Roche Ag | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
| CA3092002A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
| JP2021519073A (ja) | 2018-03-29 | 2021-08-10 | ジェネンテック， インコーポレイテッド | 哺乳動物細胞におけるラクトジェニック活性の制御 |
| AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| JP7469584B2 (ja) | 2018-06-20 | 2024-04-17 | 東ソー株式会社 | 抗体の分離方法および疾患の検査方法 |
| JP7159642B2 (ja) * | 2018-06-26 | 2022-10-25 | 東ソー株式会社 | カラムの抗体に対する保持力の測定方法 |
| US12172106B2 (en) | 2018-08-09 | 2024-12-24 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor |
| CN112955240B (zh) * | 2018-10-25 | 2022-09-16 | 豪夫迈·罗氏有限公司 | 抗体FcRn结合的修饰 |
| KR102559149B1 (ko) | 2018-10-26 | 2023-07-24 | 에프. 호프만-라 로슈 아게 | 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법 |
| CN118271445A (zh) | 2018-12-21 | 2024-07-02 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
| WO2020127873A1 (en) | 2018-12-21 | 2020-06-25 | F. Hoffmann-La Roche Ag | Antibody that binds to vegf and il-1beta and methods of use |
| CN109725159B (zh) * | 2018-12-28 | 2021-10-08 | 江苏众红生物工程创药研究院有限公司 | 人β2-微球蛋白的定量检测试纸卡与临床应用 |
| CN119716045A (zh) | 2018-12-30 | 2025-03-28 | 豪夫迈·罗氏有限公司 | 基于pH梯度SPR的结合测定 |
| KR20210134932A (ko) * | 2019-03-29 | 2021-11-11 | 에프. 호프만-라 로슈 아게 | 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 FcRn 발현 세포를 생성하는 방법 |
| TW202115115A (zh) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
| AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
| AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| CN119192386A (zh) | 2019-07-31 | 2024-12-27 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
| JP2022543551A (ja) | 2019-07-31 | 2022-10-13 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｇｐｒｃ５ｄに結合する抗体 |
| US12312414B2 (en) | 2019-09-18 | 2025-05-27 | Genentech, Inc. | Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use |
| JP7296467B2 (ja) | 2019-12-18 | 2023-06-22 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体 |
| JP7751581B2 (ja) | 2019-12-20 | 2025-10-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｉｌ－３７融合タンパク質及びその使用 |
| JP2023518841A (ja) | 2020-03-26 | 2023-05-08 | ジェネンテック， インコーポレイテッド | 宿主細胞タンパク質が減少した修飾哺乳動物細胞 |
| EP4126940A1 (en) | 2020-03-30 | 2023-02-08 | F. Hoffmann-La Roche AG | Antibody that binds to vegf and pdgf-b and methods of use |
| MX2022012541A (es) | 2020-04-15 | 2022-11-07 | Hoffmann La Roche | Inmunoconjugados. |
| MX2022015206A (es) | 2020-06-08 | 2023-01-05 | Hoffmann La Roche | Anticuerpos anti-hbv y metodos de uso. |
| TWI852680B (zh) | 2020-06-19 | 2024-08-11 | 瑞士商赫孚孟拉羅股份公司 | 與 cd3 及 cd19 結合之抗體 |
| MX2022015887A (es) | 2020-06-19 | 2023-01-24 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y folr1. |
| AR122658A1 (es) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
| WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
| WO2021262783A1 (en) | 2020-06-24 | 2021-12-30 | Genentech, Inc. | Apoptosis resistant cell lines |
| IL298921A (en) | 2020-07-10 | 2023-02-01 | Hoffmann La Roche | Antibodies that bind to cancer cells and direct radionuclides to said cells |
| CA3185122A1 (en) | 2020-07-17 | 2022-01-20 | Cecilia Pui Chi Chiu | Anti-notch2 antibodies and methods of use |
| CA3192344A1 (en) | 2020-08-28 | 2022-03-03 | Genentech, Inc. | Crispr/cas9 multiplex knockout of host cell proteins |
| PE20230986A1 (es) | 2020-09-04 | 2023-06-21 | Hoffmann La Roche | Anticuerpo que se une a vegf-a y ang2, y metodos de uso |
| TW202233671A (zh) | 2020-10-20 | 2022-09-01 | 美商建南德克公司 | Ｐｅｇ結合抗ｍｅｒｔｋ抗體及其使用方法 |
| US20220196651A1 (en) * | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| CR20230263A (es) | 2020-12-17 | 2023-08-21 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de estos |
| WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
| JP2024504931A (ja) | 2021-01-12 | 2024-02-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体 |
| US20240173442A1 (en) | 2021-01-13 | 2024-05-30 | Hoffmann-La Roche Inc. | Combination therapy |
| WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
| CN117062839A (zh) | 2021-03-12 | 2023-11-14 | 基因泰克公司 | 抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法 |
| AU2022259546A1 (en) | 2021-04-14 | 2023-11-16 | Anjarium Biosciences Ag | Fc-derived polypeptides |
| JP2024514222A (ja) | 2021-04-19 | 2024-03-28 | ジェネンテック， インコーポレイテッド | 改変された哺乳動物細胞 |
| EP4341385A1 (en) | 2021-05-21 | 2024-03-27 | Genentech, Inc. | Modified cells for the production of a recombinant product of interest |
| EP4370545A1 (en) | 2021-07-12 | 2024-05-22 | Genentech, Inc. | Structures for reducing antibody-lipase binding |
| US12240910B2 (en) | 2021-07-14 | 2025-03-04 | Genentech, Inc. | Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use |
| EP4373859A1 (en) | 2021-07-22 | 2024-05-29 | F. Hoffmann-La Roche AG | Heterodimeric fc domain antibodies |
| WO2023013618A1 (ja) * | 2021-08-02 | 2023-02-09 | 国立研究開発法人国立長寿医療研究センター | ヒトアストロウイルスの感染レセプターとその応用 |
| US20250215103A1 (en) | 2021-08-03 | 2025-07-03 | Hoffmann-La Roche Inc. | Bispecific antibodies and methods of use |
| CN118139648A (zh) | 2021-10-14 | 2024-06-04 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的替代的PD1-IL7v免疫缀合物 |
| AU2022362681A1 (en) | 2021-10-14 | 2024-04-04 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
| AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
| CN118401546A (zh) | 2021-12-15 | 2024-07-26 | 基因泰克公司 | 稳定的il-18多肽及其用途 |
| WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
| AR129268A1 (es) | 2022-05-11 | 2024-08-07 | Hoffmann La Roche | Anticuerpo que se une a vegf-a e il6 y métodos de uso |
| AU2023356218A1 (en) | 2022-10-07 | 2025-04-24 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法 |
| TW202430211A (zh) | 2022-10-10 | 2024-08-01 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及ｉｍｉｄ之組合療法 |
| TW202423969A (zh) | 2022-10-10 | 2024-06-16 | 瑞士商赫孚孟拉羅股份公司 | Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法 |
| WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
| EP4619428A1 (en) | 2022-11-15 | 2025-09-24 | F. Hoffmann-La Roche AG | Antigen binding molecules |
| CN119546630A (zh) | 2022-12-08 | 2025-02-28 | 南京诺唯赞生物科技股份有限公司 | 特异性结合rsv的抗体 |
| US20240360229A1 (en) | 2023-01-18 | 2024-10-31 | Genentech, Inc. | Multispecific antibodies and uses thereof |
| EP4651886A1 (en) | 2023-01-20 | 2025-11-26 | F. Hoffmann-La Roche AG | Immunoconjugates |
| CN120569410A (zh) | 2023-01-25 | 2025-08-29 | 豪夫迈·罗氏有限公司 | 与csf1r和cd3结合的抗体 |
| JP2026510318A (ja) | 2023-03-06 | 2026-04-02 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ＥＧＦＲｖＩＩＩ／抗ＣＤ３抗体と腫瘍標的化４－１ＢＢアゴニストの併用療法 |
| EP4676951A1 (en) | 2023-03-10 | 2026-01-14 | Genentech Inc. | Fusions with proteases and uses thereof |
| CN120936626A (zh) | 2023-03-31 | 2025-11-11 | 基因泰克公司 | 抗αvβ8整合素抗体及使用方法 |
| WO2024208777A1 (en) | 2023-04-03 | 2024-10-10 | F. Hoffmann-La Roche Ag | All-in-one agonistic antibodies |
| CN120917044A (zh) | 2023-04-03 | 2025-11-07 | 豪夫迈·罗氏有限公司 | 激动性拆分型抗体 |
| WO2024231320A1 (en) | 2023-05-08 | 2024-11-14 | F. Hoffmann-La Roche Ag | Targeted interferon alpha fusion proteins and methods of use |
| EP4713356A1 (en) | 2023-05-16 | 2026-03-25 | F. Hoffmann-La Roche AG | Pd-1-regulated il-2 immunocytokine and uses thereof |
| TW202502809A (zh) | 2023-06-22 | 2025-01-16 | 美商建南德克公司 | 抗體及其用途 |
| CN121712799A (zh) | 2023-07-26 | 2026-03-20 | 豪夫迈·罗氏有限公司 | 与cd3结合的抗体 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| AR133909A1 (es) | 2023-09-25 | 2025-11-12 | Hoffmann La Roche | ANTICUERPO QUE SE UNE A C3bBb |
| WO2025099120A1 (en) | 2023-11-09 | 2025-05-15 | F. Hoffmann-La Roche Ag | Multispecific antibodies with conditional activity |
| WO2025125386A1 (en) | 2023-12-14 | 2025-06-19 | F. Hoffmann-La Roche Ag | Antibodies that bind to folr1 and methods of use |
| US20260071002A1 (en) | 2023-12-20 | 2026-03-12 | Hoffmann-La Roche Inc. | Antibodies binding to ceacam5 |
| WO2025133290A1 (en) | 2023-12-21 | 2025-06-26 | Temper Bio | Protein for immune regulation |
| WO2025133042A2 (en) | 2023-12-22 | 2025-06-26 | F. Hoffmann-La Roche Ag | Activatable fusion proteins and methods of use |
| WO2025149633A1 (en) | 2024-01-12 | 2025-07-17 | Laigo Bio B.V. | Bispecific antigen binding proteins |
| WO2025181189A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 |
| WO2025202147A1 (en) | 2024-03-27 | 2025-10-02 | F. Hoffmann-La Roche Ag | Interleukin-7 immunoconjugates |
| WO2025215060A1 (en) | 2024-04-11 | 2025-10-16 | F. Hoffmann-La Roche Ag | Antibodies that specifically bind modified oligonucleotides |
| US20260056209A1 (en) | 2024-06-14 | 2026-02-26 | Gilead Sciences, Inc. | Anti-ccr8 antibodies and uses thereof |
| WO2026041568A1 (en) | 2024-08-20 | 2026-02-26 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and dotam |
| WO2026052654A1 (en) | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026052652A1 (en) | 2024-09-03 | 2026-03-12 | F. Hoffmann-La Roche Ag | Cytokine receptor agonist |
| WO2026073840A1 (en) | 2024-10-01 | 2026-04-09 | F. Hoffmann-La Roche Ag | Antibodies that bind to cd3 and uses therefor |
| WO2026078029A1 (en) | 2024-10-10 | 2026-04-16 | F. Hoffmann-La Roche Ag | Splitted interleukin-2 prodrugs and uses thereof |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4900660A (en) * | 1985-11-25 | 1990-02-13 | University Of Florida | Streptococcal fc rc |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| ES2052027T5 (es) | 1988-11-11 | 2005-04-16 | Medical Research Council | Clonacion de secuencias de dominio variable de inmunoglobulina. |
| US5169936A (en) * | 1989-04-14 | 1992-12-08 | Biogen, Inc. | Protein purification on immobilized metal affinity resins effected by elution using a weak ligand |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| EP1082341B1 (en) * | 1998-06-01 | 2010-12-08 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| PT1222292E (pt) | 1999-10-04 | 2005-11-30 | Medicago Inc | Metodo para regulacao da transcricao de genes exogenos na presenca de azoto |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| ES2274823T3 (es) | 1999-12-29 | 2007-06-01 | Immunogen, Inc. | Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica. |
| AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| AU2003236017B2 (en) | 2002-04-09 | 2009-03-26 | Kyowa Kirin Co., Ltd. | Drug containing antibody composition |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20050079574A1 (en) | 2003-01-16 | 2005-04-14 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| PT1692182E (pt) | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP2385069A3 (en) * | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| WO2006031370A2 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| EP1878739A1 (en) * | 2006-07-14 | 2008-01-16 | LEK Pharmaceuticals D.D. | One step IMAC (MCAC) purification of proteins |
| DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| NZ579010A (en) * | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
| JP5522723B2 (ja) * | 2007-05-21 | 2014-06-18 | ノマディックバイオサイエンス株式会社 | 新規ポリペプチド，アフィニティークロマトグラフィー用材，及びイムノグロブリンの分離及び／又は精製方法 |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| AU2008345242B2 (en) | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| KR101834999B1 (ko) | 2008-10-14 | 2018-03-06 | 제넨테크, 인크. | 이뮤노글로불린 변이체 및 그의 용도 |
| EP2365979A2 (en) | 2008-10-22 | 2011-09-21 | Biogen Idec MA Inc. | Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
| AU2010252284A1 (en) | 2009-05-27 | 2011-11-17 | F. Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| WO2011106272A1 (en) * | 2010-02-23 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel binding assays useful in identifying antibodies with altered half-lives |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| ES2692268T5 (en) * | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| EP2734537B1 (en) * | 2011-07-20 | 2022-12-21 | Zepteon, Incorporated | Polypeptide separation methods |
| EP2791171A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| LT3495387T (lt) | 2012-07-13 | 2021-11-25 | Roche Glycart Ag | Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti |
| WO2014131712A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| EP3119490B1 (en) | 2014-03-21 | 2021-09-08 | F. Hoffmann-La Roche AG | In vitro prediction of in vivo half-life of antibodies |
| EP3142700B1 (en) | 2014-05-16 | 2021-03-03 | Medimmune, LLC | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
| EP3215528B1 (en) | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| JP6288332B2 (ja) * | 2017-03-06 | 2018-03-07 | 東洋紡株式会社 | 新規なグルコース脱水素酵素 |
-
2013
- 2013-02-14 PL PL13704599T patent/PL2814587T3/pl unknown
- 2013-02-14 CN CN201380009724.6A patent/CN104125852B9/zh active Active
- 2013-02-14 WO PCT/EP2013/052932 patent/WO2013120929A1/en not_active Ceased
- 2013-02-14 EP EP13704599.3A patent/EP2814587B1/en active Active
- 2013-02-14 CA CA2860600A patent/CA2860600C/en active Active
- 2013-02-14 HR HRP20180966TT patent/HRP20180966T1/hr unknown
- 2013-02-14 KR KR1020147022694A patent/KR102069397B1/ko active Active
- 2013-02-14 BR BR112014018005-9A patent/BR112014018005B1/pt active IP Right Grant
- 2013-02-14 JP JP2014557032A patent/JP6152120B2/ja active Active
- 2013-02-14 SI SI201331082T patent/SI2814587T1/en unknown
- 2013-02-14 RU RU2014136223A patent/RU2624128C2/ru active
- 2013-02-14 US US14/378,808 patent/US20150018241A1/en not_active Abandoned
- 2013-02-14 ES ES13704599.3T patent/ES2676031T3/es active Active
- 2013-02-14 MX MX2014009622A patent/MX360352B/es active IP Right Grant
- 2013-02-14 CA CA3159061A patent/CA3159061A1/en active Pending
- 2013-02-14 TR TR2018/08458T patent/TR201808458T4/tr unknown
-
2017
- 2017-05-26 JP JP2017104130A patent/JP6360232B2/ja active Active
-
2018
- 2018-06-21 JP JP2018117501A patent/JP6713020B2/ja active Active
-
2019
- 2019-01-25 US US16/258,294 patent/US11814409B2/en active Active
-
2023
- 2023-08-17 US US18/235,015 patent/US20240124519A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015512034A (ja) | 2015-04-23 |
| BR112014018005A2 (pt) | 2018-06-26 |
| JP2017207494A (ja) | 2017-11-24 |
| JP6713020B2 (ja) | 2020-06-24 |
| CA3159061A1 (en) | 2013-08-22 |
| BR112014018005B1 (pt) | 2021-06-29 |
| JP2018188442A (ja) | 2018-11-29 |
| RU2624128C2 (ru) | 2017-06-30 |
| SI2814587T1 (en) | 2018-08-31 |
| CN104125852B9 (zh) | 2017-05-17 |
| US20190276492A1 (en) | 2019-09-12 |
| CN104125852B (zh) | 2017-03-22 |
| CA2860600C (en) | 2022-07-26 |
| TR201808458T4 (tr) | 2018-07-23 |
| KR20140127251A (ko) | 2014-11-03 |
| WO2013120929A1 (en) | 2013-08-22 |
| EP2814587B1 (en) | 2018-05-02 |
| EP2814587A1 (en) | 2014-12-24 |
| CA2860600A1 (en) | 2013-08-22 |
| US20150018241A1 (en) | 2015-01-15 |
| MX2014009622A (es) | 2014-11-10 |
| HRP20180966T1 (hr) | 2018-08-10 |
| US20240124519A1 (en) | 2024-04-18 |
| HK1203435A1 (en) | 2015-10-30 |
| ES2676031T3 (es) | 2018-07-16 |
| CN104125852A (zh) | 2014-10-29 |
| US11814409B2 (en) | 2023-11-14 |
| RU2014136223A (ru) | 2016-04-10 |
| JP6360232B2 (ja) | 2018-07-18 |
| MX360352B (es) | 2018-10-30 |
| JP6152120B2 (ja) | 2017-06-21 |
| KR102069397B1 (ko) | 2020-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2521524B (en) | Chromatographic materials | |
| SMT202000689T1 (it) | Reagenti per sirp-alfa ad alta affinita' | |
| EP2817075A4 (en) | CHROMATOGRAPHY COLUMN PREPARATIVE | |
| ZA201406525B (en) | N-cycl ylamides as nematicides | |
| EP2894171A4 (en) | ADSORPTION | |
| IL243414A0 (en) | Affinity chromatography matrix | |
| EP2562178A4 (en) | CHARGE FOR AFFINITY CHROMATOGRAPHY | |
| EP2874517A4 (en) | SEAT LIFTING ARRANGEMENT | |
| GB201020148D0 (en) | Chromatography column | |
| PT3915659T (pt) | Suporte de afinidade | |
| AP2015008289A0 (en) | Trommel assembly | |
| EP2905847A4 (en) | TOGETHER | |
| HUE054362T2 (hu) | Foszfolipáz D4 elleni antitest | |
| EP2842997A4 (en) | FLUORINATED RESIN COMPOSITION | |
| GB2500244B (en) | Clamp assembly | |
| GB2506845B (en) | Modified tubular | |
| GB201020146D0 (en) | Chromatography column | |
| GB2500087B (en) | Clamp assembly | |
| GB2503496B (en) | Vehicle assembly | |
| EP2803993A4 (en) | AUTOMATIC SAMPLER | |
| AU346758S (en) | Chromatography column | |
| GB201500762D0 (en) | Sorbents | |
| EP3042192A4 (en) | Weak affinity chromatography | |
| AU346759S (en) | Chromatography system | |
| PH32012000846S1 (en) | Tricycle |